The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?
Open accessAbstract
Specific mutations in epidermal growth factor receptor (EGFR) gene are predictive for response to the EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients (NSCLC). According to international guidelines, the molecular testing in patients with advanced NSCLC of a non-squamous subtype is recommended. However, obtain a tissue sample could be challenging. Liquid biopsy allows to determine patients suitable for EGFR-targeted therapy by analysis of circulating-free tumor DNA (cfDNA) in peripheral blood samples and might replace tissue biopsy. It allows to acquire a material in convenient minimally invasive manner, is easily repeatable, could be used for molecular identification and molecular changes monitoring. Many studies show a high concordance rate between tissue and plasma samples testing. When U.S. Food and Drug Administration (FDA) approved the first liquid biopsy test, analysis of driver gene mutation from cfDNA becomes a reality in clinical practice for patients with NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Douillard, J.-Y., Ostoros, G., Cobo, M., Ciuleanu, T., Cole, R., McWalter, G., Walker, J., Dearden, S., Webster, A., Milenkova, T., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000263 · Cited by 448
Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
Taniguchi, K., Uchida, J., Nishino, K., Kumagai, T., Okuyama, T., Okami, J., Higashiyama, M., Kodama, K., Imamura, F., & Kato, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1712 · Cited by 315
Reckamp, K. L., Melnikova, V. O., Karlovich, C., Sequist, L. V., Camidge, D. R., Wakelee, H., Perol, M., Oxnard, G. R., Kosco, K., Croucher, P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.035 · Cited by 287
Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229
Cited by
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Keller, L., Belloum, Y., Wikman, H., & Pantel, K. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01047-5 · Cited by 401
Tracking cancer progression: from circulating tumor cells to metastasis
Castro-Giner, F., & Aceto, N. (2020) · Genome Medicine · doi:10.1186/s13073-020-00728-3 · Cited by 363
ctDNA as a cancer biomarker: A broad overview
Pessoa, L. S., Heringer, M., & Ferrer, V. P. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103109 · Cited by 298
Application of liquid biopsy in bone and soft tissue sarcomas: Present and future
Li, X., Seebacher, N. A., Hornicek, F. J., Xiao, T., & Duan, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.012 · Cited by 53
Network approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
Metadata
- Authors
- Kwapisz, D.
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2017-02
- Volume
- 5
- Issue
- 3
- Pages
- 46-46
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- OpenAlex
- W2975734135
- Cited by
- 271
- References
- 7
- FWCI
- 25.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? https://app.cochat.ai/papers/10.21037/atm.2017.01.32
- The paper
- Kwapisz, D. (2017). The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Annals of Translational Medicine. https://doi.org/10.21037/atm.2017.01.32
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
